Joseph Civantos, MD
Retina Specialist · Harvey, ILNPI 1336149053
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (48.8%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 83.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $3,791 and has fallen 96.8% since, to $121 in 2025.
Across 34 payments — averaging $200.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$6K
- Regeneron Healthcare Solutions, Inc.$340
- Astellas Pharma US Inc$229
- Genentech USA, Inc.$209
- Alcon$125
- Coherus Oncology, Inc.$74
- plus $124 from 6 others
Across 89 payments — averaging $7171.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$638K
What the payments were for
- Food & beverage$1,10116%
- Ownership interest$2,38635%
- Other$3,32649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $5,712 |
| Regeneron Healthcare Solutions, Inc. | 9 | $340 |
| Astellas Pharma US Inc | 2 | $229 |
| Genentech USA, Inc. | 6 | $209 |
| Alcon | 1 | $125 |
| Coherus Oncology, Inc. | 3 | $74 |
| AbbVie | 1 | $25 |
| Alimera Sciences, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $21 |
| Heidelberg Engineering, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$125
- EYLEA$100
How this compares
$6,813 in reported general payments places this provider in the 70th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 126 | $5,984 |
| Timolol Maleate | 65 | $2,380 |
| Brimonidine Tartrate | 68 | $2,135 |
| Ketorolac Tromethamine | 98 | $1,886 |
| Latanoprost | 84 | $1,180 |
| Atropine Sulfate | 14 | $687 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $519 |
| Dorzolamide Hcl | 18 | $466 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Harvey
- Mathew MaccumberHarvey$219K
- Kourous RezaeiHarvey$126K
- Kirk PackoHarvey$86K
- David OrthHarvey$70K
- Timothy FloodHarvey$57K
- Serge DebustrosHarvey$34K
- Vivek ChaturvediHarvey$34K
- Sohail HasanHarvey$30K
- Jack CohenHarvey$24K
- Zac RavageHarvey$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.